Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems Inc (TIVC) delivers innovative bioelectronic solutions through its non-invasive microcurrent therapies, most notably the ClearUP Sinus Relief device. This page provides direct access to all official corporate announcements, financial disclosures, and therapeutic development updates.
Investors and healthcare professionals will find chronologically organized press releases covering regulatory milestones, clinical study results, and partnership agreements. Our repository includes quarterly earnings reports, product launch details, and scientific validation updates – all essential for understanding TIVC's position in the health technology sector.
Key focus areas include advancements in bioelectronic treatment platforms, market expansion initiatives, and peer-reviewed research findings. Content is rigorously verified to ensure alignment with SEC filings and medical device regulations. Bookmark this page for efficient tracking of material developments affecting TIVC's therapeutic innovations and business trajectory.
Tivic Health Systems, Inc. (TIVC) announced that its ClearUP® Sinus Pain Relief device has been awarded the Most Innovative Sinus Relief Solution for 2022 by Global Health & Pharma. This recognition marks the second consecutive year for ClearUP, which is FDA-cleared and clinically proven to alleviate sinus pain and congestion. The company aims to further develop bioelectronic treatments for various conditions, reflecting a shift towards non-invasive medical solutions. Recent accolades enhance Tivic's visibility in the health tech space, signaling strong market potential.
Tivic Health Systems (Nasdaq: TIVC) announced its Annual General Meeting of Shareholders to be held virtually on June 14, 2022, at 10:00 AM PDT. This format aims to ensure accessibility for all shareholders. Related documents and information can be found on Tivic Health's website and the SEC's website. The company specializes in non-invasive bioelectronic treatments for inflammation and related conditions. Forward-looking statements in the release highlight inherent risks and uncertainties affecting future performance.
Tivic Health Systems, Inc. (TIVC) reported a strong first quarter 2022 with a 33% increase in net revenue to $428K compared to $323K in Q1 2021. Notably, gross profit surged 219% to $70K, driven by a 77% growth in direct-to-consumer unit sales. Overall unit sales rose by 28%, aided by the termination of less profitable retail arrangements. However, total expenses rose significantly, including $684K in sales and marketing, reflecting increased advertising and e-commerce efforts. Cash reserves stood at approximately $10.8 million as of March 31, 2022.
Jennifer Ernst, CEO of Tivic Health, will speak at FORTUNE Brainstorm Health on May 11, participating in a panel titled Driving Digital Health: Where Wearables Are Headed Next. The event, held in Los Angeles on May 10-11, 2022, focuses on the intersections of health care and technology, highlighting innovations that enhance health outcomes. Ernst's recent accolades include recognition as one of the Inc 100 Female Founders and a leader in Consumer Healthcare.
For more on Tivic Health, visit tivichealth.com.
Tivic Health Systems, Inc. (Nasdaq: TIVC) will report its Q1 2022 financial results on May 16, 2022, at 1:30 pm PT (4:30 pm ET) via conference call and webcast. Investors can access the call at this link. The company focuses on non-invasive bioelectronic treatments for inflammation and related conditions. For further information, visit Tivic Health's website.
Tivic Health® Systems, Inc. (Nasdaq: TIVC) announced its fourth quarter 2021 financial results and year-end shareholder update via conference call on April 19, 2022. The call is scheduled for 2:00 pm PT / 5:00 pm ET, providing insights into the company’s performance in the bioelectronic medicine sector. Interested participants can join by calling the toll-free number 888-506-0062 or the international number 973-528-0011 with the access code 689084. Tivic Health focuses on non-invasive treatments for inflammation and related conditions.
Tivic Health Systems (Nasdaq: TIVC) announced key executive appointments, effective April 1, 2022.
Tivic Health (Nasdaq: TIVC), a healthtech company specializing in bioelectronic medicine, was featured in an ABC News story highlighting new bioelectronic technologies for managing conditions like sinus pain and arthritis. ClearUP® Sinus Pain Relief, the only commercially available product showcased, is part of the company's growth strategy following a $17.2 million IPO in November 2021. The company is advancing its Gen2 product and exploring new applications in bioelectronic therapies as alternatives to opioids.